Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2000-03-01
2002-11-05
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S045000, C424S046000, C425S006000, C425S007000, 26, 26, 26, 26, C514S958000
Reexamination Certificate
active
06475524
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to a process for converting amorphous and/or meta-stable crystalline regions of particles into a crystalline state, the resulting particles being useful e.g. for oral or nasal inhalation.
BACKGROUND OF THE INVENTION
The increasing production and use of fine powders in the pharmaceutical industry has high-lighted the need for reliable methods for assessing their physicochemical and technical handling. Particles obtained by spray drying, freeze drying, rapid solvent quenching or from controlled precipitation will often be in an amorphous state and/or in a meta-stable crystalline form. For crystalline substances, a diminution operation, e.g. micronization, will give particles with amorphous regions.
The usefulness of amorphous and/or meta-stable crystalline particles is limited due to their thermodynamic instability. For example, such particles tend to fuse in the presence of moisture, thereby forming hard agglomerates which are difficult to break up. Furthermore, amorphous and/or meta-stable crystalline particles exhibit larger batch-to-batch variations as regards bulk density than do well-defined crystalline particles. This may cause problems e.g. in inhalers for treating respiratory disorders, due to lower dosing accuracy.
It is therefore desirable to convert the amorphous or meta-stable crystalline particles into a crystalline, and therefore, more stable state.
Methods to convert the amorphous or meta-stable crystalline particles into crystalline particles are known. Examples are disclosed in U.S. Pat. No. 5,709,884 and U.S. Pat. No. 5,562,923 both to Astra AB of Sweden.
The known methods to convert amorphous or meta-stable crystalline particles into crystal-line particles are, however, often time consuming requiring substantial space. Therefore, there is a need for a more efficient technique for producing crystalline particles with a high shelf life.
SUMMARY OF THE INVENTION
The object of the present invention is to provide a process for crystallization of amorphous and/or meta-stable crystalline regions of particles e.g. obtained in a preceding micronization stage, comprising treating the particles under supercritical or subcritical conditions with an anti-solvent and a solvent.
According to a preferred embodiment of the invention, the anti-solvent and solvent are carbon dioxide and water, respectively.
According to another preferred embodiment, the relative solvent saturation of the anti-solvent lies in the range of from 15% up to 50% of total solvent saturation at the prevailing pressure and temperature.
REFERENCES:
patent: 5562923 (1996-10-01), Trofast et al.
patent: 5851453 (1998-12-01), Hanna et al.
patent: 6063138 (2000-05-01), Hanna et al.
patent: 0677332 (1995-10-01), None
patent: 9501221 (1995-01-01), None
patent: 9505805 (1995-03-01), None
patent: 9629998 (1996-10-01), None
patent: 9841193 (1998-09-01), None
Darcy et al., Pharmaceutical Development and Technology, 3(4), 503-507 (1998).
Palakodaty et al., World Congress on Particle Technology 3, 4067-4078 (1998).
Bisrat Mikael
Demirbüker Mustafa
Moshashaee Saeed
Nyqvist Håkan
AstraZeneca AB
Channavajjala Lakshmi
Page Thurman K.
White & Case LLP
LandOfFree
Composition of matter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition of matter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition of matter will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2944936